[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].

Abstract

The development of novel direct antiviral agents (DAAs) against hepatitis C virus (HCV) has represented a breakthrough in the treatment of chronic hepatitis C. Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). In genotype 1 monoinfected… (More)
DOI: 10.1016/S0213-005X(13)70113-7

Topics

Cite this paper

@article{Porcuna2013UpdateOH, title={[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].}, author={Natalia Chueca Porcuna and Marta {\'A}lvarez Est{\'e}vez and Jorge Parra Ruiz and Jos{\'e} Hern{\'a}ndez Quero and Federico Garc{\'i}a Garc{\'i}a}, journal={Enfermedades infecciosas y microbiologia clinica}, year={2013}, volume={31 Suppl 1}, pages={40-7} }